師資
周啟璠，浙江臺(tái)州人，現(xiàn)任南方科技大學(xué)格拉布斯研究院研究助理教授（副研究員），生物技術(shù)副高級(jí)工程師。2019年于沈陽藥科大學(xué)獲得藥物化學(xué)專業(yè)博士學(xué)位，師從陳國良教授，并榮獲國家獎(jiǎng)學(xué)金。主要從事腫瘤、病毒和炎癥相關(guān)疾病的小分子創(chuàng)新藥物研究與開發(fā)。于2020年加入南方科技大學(xué)張緒穆教授課題組，作為項(xiàng)目骨干參與新型口服抗新冠藥物SHEN26的臨床前研究工作 (成果發(fā)表于Science子刊-Science Translational Medicine)。后成功開發(fā)另一種更有優(yōu)勢的GS-441524前藥ATV014，為口服有效的抗SARS-CoV-2感染藥物，目前已完成臨床III期研究，進(jìn)入上市申請階段 (成果發(fā)表于Nature子刊-Signal Transduction and Targeted Therapy)。近5年在JMC, STM, STTT, EJMC等期刊發(fā)表SCI論文30余篇，申請發(fā)明專利26篇，其中作為主要發(fā)明人獲得中國專利授權(quán)17項(xiàng) 。
研究領(lǐng)域：
1. 基于病毒共性靶標(biāo)的小分子藥物開發(fā)；
2. 發(fā)展基于新機(jī)制、新靶點(diǎn)的抗腫瘤、抗炎和抗病毒小分子抑制劑
學(xué)術(shù)成果：
Yuanguang Chen, # Yongqing Liu, # Guanguan Li, # Chao Peng, Dizhen Liang, Sidi Yang, Peisen Zheng, Shuo Li, Deyin Guo, Qifan Zhou,* and Xumu Zhang *. Preclinical characterization and anti-RSV efficacy of an oral C-nucleoside derivative. Acta Pharmaceutica Sinica B, 2025, Accepted.
Peisen Zheng, Guanguan Li, Yuanguang Chen, Shuo Li, Sidi Yang, Deyin Guo, Qifan Zhou* and Xumu Zhang*. Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment. Bioorganic & Medicinal Chemistry Letters, 2025, 124, 130243.
Yongqing Liu1, Haobin Li1, Dizhen Liang1, Yuanguang Chen, Kunyu Lu, Hongqi Tao, Yuanmei Wen, Fan Pan, Xumu Zhang, Shuwen Liu* and Qifan Zhou*. Harnessing hydrophobic tag technology to combat drug-resistant influenza: design, synthesis and potency of oseltamivir-derived HyTTDs. New Journal of Chemistry, 2025, 49, 5489-5504.
Yongzhi Chen1, Kunyu Lu1, Binhao Rong1, Yuanmei Wen, Guanguan Li, Shuo Li, Deyin Guo, Qifan Zhou*, Shuwen Liu*, Xumu Zhang*. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry, 2024, https://doi.org/10.1021/acs.jmedchem.4c01979.
Fan Pan1, Qifan Zhou*,1, Ming Yan1, Sidi Yang1, Ruiyu Hu, Yongzhi Chen, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Yingjun Li, Hongmin Zhang*, Deyin Guo*, Xumu Zhang*. Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities. Bioorganic Chemistry, 2024, 154, 107988.
Yongzhi Chen1, Qifan Zhou**,1, Fan Pan, Binhao Rong, Renwei Xiao, Yuanmei Wen, Jingyuan Song, Zhengchao Tu, Shuwen Liu****, Yingjun Li***, Xumu Zhang*. Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives. European Journal of Medicinal Chemistry, 2024, 280, 116922.
Qishu Chen1, Qifan Zhou1,*, Sidi Yang1, Fan Pan, Hongqi Tao, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Deyin Guo*, Yingjun Li*, Xumu Zhang*. Identification of adenosine analogues as nsp14 N7?methyltransferase inhibitors for treating coronaviruses infection. Bioorganic Chemistry, 2024, 153, 107894.
Qishu Chen1, Qifan Zhou1, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2024, 28, 2188-2195.
Qifan Zhou1, Sidi Yang1, Liu Cao1, Yang Yang1, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27.
Qifan Zhou1, Yinzhu Luo1, Yujun Zhu1, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249.
Liu Cao1, Yingjun Li1, Sidi Yang1, Guanguan Li1, Qifan Zhou1, Jing Sun1, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621.
Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255.
Fangyu Du1, Qifan Zhou1, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083.
Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N?arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167.
Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941.
Chunling Yuan1, Xiaoli Guo1, Qifan Zhou1, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer’s disease-related pathologies and cognitive impairments by increasing -amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180.
Yajie Shi1, Qifan Zhou1, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090.
Fangyu Du1, Qifan Zhou1, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168.
Fangyu Du1, Qifan Zhou1, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N–tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554.
Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508.
Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420.
Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586.
Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485.
Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50.
Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798.
Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446.
Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610.
Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784.